Research & Studies
Share your love
UCL-Moorfields Eye Hospital Secures £5M for Research Center
The Sir Jules Thorn Charitable Trust has allocated £5 million towards the establishment of a research center within Oriel, the collaborative initiative between UCL and Moorfields Eye Hospital aimed at advancing eye health. Partnering with Moorfields Eye Charity and Moorfields…
Australian Government Funds $35M Cornea Facility
The Australian Government is making significant strides in the global fight against blindness by allocating funds for the establishment of a state-of-the-art manufacturing facility for artificial corneas. The University of Sydney has been designated to receive $35 million through the…
New Experimental Drug Shows Promise in Treating DME
A recent study published in Nature Medicine has unveiled promising insights into a potential breakthrough in the treatment of Diabetic Macular Edema (DME). The study suggests that an experimental drug, part of a new class of therapeutics called “senolytics,” could…
Toku Granted CE and UKCA Marks for CLAiR Technology
Toku announced the acquisition of the CE Mark in Europe and UKCA certification in the United Kingdom for its patented CLAiR technology. This innovation offers a non-invasive method for assessing the risk of cardiovascular disease (CVD) directly at the point…
Iridex Granted European Patent for MicroPulse Technology
Iridex, a pioneering company in the field of medical devices, announced the grant of the European Patent ‘EP 3009093.’ This patent, titled “Laser System with Short Pulse Characteristics and its Methods of Use,” signifies a significant milestone for the company,…
Negative Effect of Atropine Drops After Glaucoma Surgery
According to a report by an international team of researchers, atropine instillation after trabeculectomy should be discouraged since it causes greater and longer lasting reduction in visual quality.1 The study’s lead author is Panagiotis Laspas, MD, of the Department of…
Perfluorohexyloctane Drops Help Alleviate Dry Eye
According to recent research, perfluorohexyloctane eye drops (SHR8058) demonstrated significant improvement in both the signs and symptoms of dry eye disease (DED) linked to meibomian gland dysfunction (MGD) with rapid effectiveness in Chinese patients. The findings showed that the perfluorohexyloctane…
Treatment of Intraocular Melanoma | OBN
Melanoma of the uveal tract (iris, ciliary body, and choroid), though rare, is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people,…
4DMT Reports Positive Interim Data for Wet AMD Treatment
4D Molecular Therapeutics (4DMT) announced positive interim data from the Phase 2 PRISM clinical trial, marking a significant stride in the treatment of wet age-related macular degeneration (wet AMD). Arshad M. Khanani, MD, MA, FASRS, presented the data at the…
Kiora, Théa Partner for Retinal Disease Treatment
Kiora Pharmaceuticals has joined forces with Théa Open Innovation (TOI), a sister company of Laboratoires Théa, to develop and commercialize KIO-301 for the treatment of degenerative retinal diseases. The strategic agreement grants Théa exclusive worldwide development and commercialization rights, excluding…